Among these, the CellSearch system is currently the only technology approved by the FDA for determining the prognosis of patients with advanced breast, prostate, and colorectal cancer through CTC enrichment [11] expressing epithelial cell adhesion molecules (EpCAM) and cytokeratin [14,17]. The gene discussed is EPCAM; the disease is colorectal cancer.